Description
Trade name:
Symbicort 160
Compound:
Each dose contains:
budesonide micronized 160 mcg
formoterol fumarate dihydrate 4.5 mcg
Auxiliary components:
lactose monohydrate 730 mcg.
Properties:
Symbicort contains budesonide and formoterol, which have different mechanisms of action and exhibit an additive effect in reducing the frequency of exacerbations of bronchial asthma. The special properties of budesonide and formoterol make it possible to use their combination to relieve attacks/symptoms with an anti-inflammatory effect, or as maintenance therapy for bronchial asthma.
Indications:
Bronchial asthma, to achieve general control of the disease, including prevention and relief of symptoms, and reduction of the risk of exacerbations, also for the treatment of bronchial asthma of any severity, if it is appropriate to use inhaled GCS;
COPD, as symptomatic therapy in patients with post-bronchodilator FEV1 <70% predicted and with a history of exacerbations despite regular bronchodilator therapy.
Method of administration and dosage:
The dosage of the drugs included in the Symbicort preparation is selected individually and depending on the severity of the disease. This must be taken into account not only when starting treatment with combination drugs, but also when changing the maintenance dose of the drug.
Patients should be under constant medical supervision to ensure adequate dosage of Symbicort.
Recommended dosage:
Adults over 18 years: 1-2 inhalations 2 times a day, maximum 4 times a day
Patients 12-17 years old: 1-2 inhalations 2 times a day
Children over 6 years of age (Symbicort is indicated for use at a dosage of 80 mcg) 2 inhalations 2 times a day
Symbicort is not recommended for children under 6 years of age.
Contraindications:
-hypersensitivity to budesonide, formoterol or inhaled lactose;
– children under 6 years of age;
lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
With caution: pulmonary tuberculosis (active or inactive forms), fungal, viral or bacterial infections of the respiratory system.
Precautions:
During therapy with Symbicort, exacerbations and development of serious adverse events associated with bronchial asthma may occur. Patients should continue treatment but seek medical advice if asthma symptoms are not controlled or if their condition worsens after starting therapy.
Side effects:
From the nervous system: often headache; anxiety, nausea, dizziness, sleep disturbances;
From the cardiovascular system: often a feeling of palpitations;
From the respiratory system: often candidiasis of the mucous membrane of the oral cavity and pharynx, cough, hoarseness, mild irritation in the throat;
Allergic reactions: rare immediate and delayed hypersensitivity reactions (eg, urticaria, angioedema, anaphylactic reactions).
Storage method:
Store in a dry, dark, cool place at a temperature not exceeding 30 degrees.
